Sensus Healthcare, Inc. (SRTS) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Sensus Healthcare, Inc. is a medical device company specializing in superficial radiation therapy (SRT) for oncological and non-oncological skin conditions. The Company operates as a single segment from its headquarters in Boca Raton, Florida, and utilizes third-party manufacturing. In 2024, the Company formed a subsidiary, Sensus Healthcare Services, LLC, to provide operational healthcare services to dermatology clinics.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $41.8 million | $24.4 million |
| Gross Profit | $24.4 million | $14.1 million |
| Gross Margin | 58.4% | 57.8% |
| Net Income | $6.6 million | $0.5 million |
| Operating Income | $8.1 million | ($0.4 million) loss |
| Cash and Equivalents | $22.1 million | $23.1 million |
| Debt | $0 (No borrowings) | $0 (No borrowings) |
| Operating Cash Flow | ($0.8 million) used | ($2.1 million) used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 71% year-over-year, driven by a significant increase in unit sales (115 units in 2024 vs. 67 units in 2023).
- Profitability: The Company transitioned from an operating loss of $0.4 million in 2023 to an operating income of $8.1 million in 2024. Net income surged to $6.6 million from $0.5 million.
- Customer Concentration: Concentration risk increased; a single U.S. customer accounted for 73% of 2024 revenue (up from 61% in 2023) and 86% of accounts receivable.
- Accounts Receivable: Net accounts receivable increased 86% to $19.7 million, primarily due to extended payment terms with the primary customer.
- Expense Management: Selling and marketing expenses decreased 11% due to lower headcount and reduced agency/travel costs, while General and Administrative expenses rose 37% due to higher compensation and bad debt expenses.
Outlook, Risks, and Contingencies
- Liquidity: The Company maintains $22.1 million in cash and has a $15 million revolving credit facility (amended in October 2024) with no outstanding borrowings. Management believes resources are sufficient for the next 12 months.
- Regulatory & Legal: The Company is cooperating with a Department of Justice investigation regarding Medicare billing by a physician using Sensus products. The Company disputes any wrongdoing and has not estimated potential costs. No material legal liabilities have been recorded.
- Internal Controls: A material weakness in IT general controls identified in mid-2024 has been remediated as of December 31, 2024.
- Risks: Key risks include reliance on a single customer for the majority of revenue, dependence on a single preferred supplier for x-ray tubes, and potential changes in third-party payer reimbursement policies.
- Guidance: The Company expects 2025 R&D expenses to be generally consistent with 2024 levels. No specific revenue guidance was provided in the text.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the relationship with the single customer representing 73% of revenue and 86% of receivables.
- Cash Flow vs. Net Income: Analyze the divergence between strong net income ($6.6M) and negative operating cash flow ($0.8M), driven by the buildup in accounts receivable.
- DOJ Investigation: Monitor updates regarding the Department of Justice investigation into Medicare billing practices involving Sensus devices.
- Supply Chain: Assess the risk associated with the single preferred supplier for critical x-ray tube components.
- Reimbursement Policy: Track any changes in Medicare or private payer reimbursement rates for SRT procedures, which could impact future demand.